Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis

Brain

Volumn 138, Issue 3, 2015, Pages 517-539

  Weisfeld Adams, James D ^a,b,c   Sand, Ilana B Katz ^c   Honce, Justin M ^a   Lublin, Fred D ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Inherited disease; Misdiagnosis; Mitochondrial disease; Multiple sclerosis

Indexed keywords

ARTERY DISEASE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DISORDERS OF PEROXISOMAL FUNCTIONS; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; LEUKODYSTROPHY; LEUKOENCEPHALOPATHY; LYSOSOME STORAGE DISEASE; MENDELIAN DISORDER; MULTIPLE SCLEROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPINAL CORD DISEASE; COMPLICATION; GENETICS; MITOCHONDRIAL DISEASES;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MITOCHONDRIAL DISEASES; MULTIPLE SCLEROSIS;

EID: 84927954285     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu397     Document Type: Review

References (119)

1. Aghakhanyan G, Martinuzzi A, Frijia F, Vavla M, Hlavata H, Baratto A, et al. Brain white matter involvement in hereditary spastic paraplegias: analysis with multiple diffusion tensor indices. Am J Neuroradiol 2014; 35: 1533-8.
2. Alpayci M, Bozan N, Erdem S, Gunes M, Erden M. The possible underlying pathophysiologic mechanisms for development of multiple sclerosis in familial Mediterranean fever. Med Hypotheses 2012; 78: 717-20.
3. Balbi P, Salvini S, Fundarò C, Frazzitta G, Maestri R, Mosah D, et al. The clinical spectrum of late-onset Alexander disease; a systematic literature review. [Review]. J Neurol 2010; 257: 1955-62.
4. Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies and future directions. [Review]. Lancet Neurol 2007; 6: 887-902.
5. Barnerias C, Saudubray JM, Touati G, De Lonlay P, Dulac O, Ponsot G, et al. Pyruvate dehydrogenase complex deficiency: four neurological phenotypes with differing pathogenesis. Dev Med Child Neurol 2010; 52: e1-9.
6. Baronica KB, Mlinac K, Ozretić D, Vladić A, Bognar SK. Arylsulfatase A gene polymorphisms in relapsing remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression. Coll Antropol 2011; 35 (Suppl 1): 11-16.
7. Battini R, Bianchi MC, Boespflug-Tanguy O, Tosetti M, Bonanni P, Canapicchi R, et al. Unusual clinical and magnetic resonance imaging findings in a family with proteolipid protein gene mutation. Arch Neurol 2003; 60: 268-72.
8. Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, et al. International Multiple Sclerosis Genetics Consortium (IMSGC).Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45: 1353-60.
9. Bhidayasiri R, Perlman SL, Pulst SM, Geschwind DH. Late-onset Friedreich ataxia: phenotypic analysis, magnetic resonance imaging findings, and review of the literature. Arch Neurol 2005; 62: 1865-9.
10. Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachrom-atic leukodystrophy. Science 2013; 341: 1233158.
11. Böttcher T, Rolfs A, Tanislav C, Bitsch A, Köhler W, Gaedeke J, et al. Fabry disease-Underestimated in the differential diagnosis of multiple sclerosis? PLoS One 2013; 8: e7189.
12. Boustany RM. Lysosomal storage diseases-the horizon expands. [Review]. Nat Rev Neurol 2013; 9: 583-98.
13. Burlina AP, Manara R, Caillaud C, Laissy JP, Severino M, Klein I, et al. The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol 2008; 255: 738-44.
14. Bylesjö I, Brekke OL, Prytz J, Skjeflo T, Salvesen R. Brain magnetic resonance imaging white matter lesions and cerebrospinal fluid findings in patients with acute intermittent porphyria. Eur Neurol 2004; 51: 1-5.
15. Camiña-Tato M, Morcillo-Suárez C, Bustamante MF, Ortega I, Navarro A, Muntasell A, et al. Gender-associated differences of perforin polymorphisms in the susceptibility to multiple sclerosis. J Immunol 2010; 185: 5392-404.
16. Carra-Dalliere C, Scherer C, Ayrignac X, Menjot de Champfleur N, Bellesme C, Labauge P, et al. Adult-onset cerebral X-linked adreno-leukodystrophy with major contrast-enhancement mimicking acquired disease. Clin Neurol Neurosurg 2013; 115: 1906-7.
17. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Bougnères P, Schmidt M, Kalle CV, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326: 818-23.
18. Casali C, Valente EM, Bertini E, Montagna G, Criscuolo C, De Michele G, et al. Clinical and genetic studies in hereditary spastic paraplegia with thin corpus callosum. Neurology 2004; 62: 262-8.
19. Chebel S, Barboura I, Boughammoura-Bouatay A, Ammar M, Ferchichi S, Miled A, et al. Adult-type metachromatic leukodystro-phy mimicking multiple sclerosis. Can J Neurol Sci 2009; 36: 521-3.
20. De Beer M, Engelen M, van Geel BM. Frequent occurrence of cerebral demyelination in adrenomyeloneuropathy. Neurology 2014; 83: 2227-31.
21. De Stefano N, Dotti MT, Mortilla M, Federico A. Magnetic resonance imaging and spectroscopic changes in brains of patients with cere-brotendinous xanthomatosis. Brain 2001; 124: 121-31.
22. Degos B, Laforet P, Jardel C, Sedel F, Jossay-Winter M, Romero NB, et al. POLG mutations associated with relapsing-remitting neurological events. J Clin Neurosci 2014; 21: 186-8.
23. Depienne C, Bugiani M, Dupuits C, Galanaud D, Touitou V, Postma N, et al. Brain white matter oedema due to ClC-2 chlroride channel deficiency: an observational analytical study. Lancet Neurol 2013; 12: 659-68.
24. Engelen M, Kemp S, de Visser M, van Geel BM, Wanders RJ, Aubourg P, et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up, and management. Orphanet J Rare Dis 2012; 7: 51.
25. Engelen M, Barbier M, Dijkstra IM, Schür R, de Bie RM, Verhamme C, et al. X-linked adrenoleukodystrophy in women: a cross-sectional cohort study. Brain 2014; 137 (Pt 3): 693-706.
26. Engell T. A clinic-pathoanatomical study of multiple sclerosis diagnosis. [Review]. Acta Neurol Scand 1988; 78: 39-44.
27. Escolar ML, Poe MD, Provenzale JM, Richards KC, Allison J, Wood S, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005; 352: 2069-81.
28. Farina L, Bizzi A, Finocchiaro G, Pareyson D, Sghirlanzoni A, Bertagnolio B, et al. MR Imaging and Proton MR Spectroscopy in Adult Krabbe Disease. AJNR Am J Neuroradiol 2000; 21: 1478-82.
29. Farina L, Pareyson D, Minati L, Ceccherini I, Chiapparini L, Romano S, et al. Can MR imaging diagnose adult-onset alexander disease? AJNR Am J Neuroradiol 2008; 29: 1190-6.
30. Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. [Review]. Nat Rev Neurol 2014; 10: 225-38.
31. Fukutake T, Hirayama K. Familial young-adult-onset arteriosclerotic leukoencephalopathy with alopecia and lumbago without arterial hypertension. Eur Neurol 1995; 35: 69-79.
32. Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory disgnostics of Fabry disease-recommendations of a European expert group. J Inherit Metab Dis 2011; 34 (2): 509-14.
33. Godeiro-Junior C, Felicio AC, Benites V, Chieia MA, Oliveira AS. Late-onset hexosaminidase A deficiency mimicking primary lateral sclerosis. Arq Neuropsiquiatr 2009; 67: 105-6.
34. Hanemann CO, Bergmann C, Senderek J, Zerres K, Sperfeld AD. Transient, recurrent, white matter lesions in X-linked Charcot-Marie-Tooth disease with novel Connexin 32 mutation. Arch Neurol 2003; 60: 605-9.
35. Harding AE, Sweeney MG, Miller DH, Mumford CJ, Kellar-Wood H, Menard D, et al. Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mutation. Brain 1992; 115: 979-89.
36. Harding AE. Hereditary spastic paraplegias. [Review]. Semin Neurol 1993; 13: 333-6.
37. Haworth JC, Dilling LA, Surtees RAH, Seargeant LE, Lue-Shing H, Cooper BA, et al. Symptomatic and asymptomatic methylenetetra-hydrofolate reductase deficiency in two adult brothers. Am J Med Genet 1993; 45: 572-6.
38. Hayflick SJ, Hartman M, Coryell J, Gitschier J, Rowley J. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol 2006; 27: 1230-3.
39. Hourani R, El-Hajj T, Barada WH, Hourani M, Yamout BI. MR imaging findings in autosomal recessive hereditary spastic paraplegia. Am J Neuroradiol 2009; 30: 936-40.
40. Huemer M, Scholl-Bürgi S, Hadaya K, Kern I, Beer R, Seppi K, et al. Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy. Orphanet J Rare Dis 2014; 9: 161.
41. Hurst S, Garbern J, Trepanier A, Gow A. Quantifying the carrier female phenotype in Pelizaeus-Merzbacher disease. Genet Med 2006; 8: 371-8.
42. Iñiguez C, Arenas J, Montoya J, Mostacero E, Lopez del Val J, Morales F. Mitochondrial respiratory chain deficiency may present as multiple sclerosis. Neurologia 1998; 13: 199-203.
43. Inglese M, Rovaris M, Bianchi S, Mantia LL, Mancardi GL, Ghezzi A, et al. Magnetic resonance imaging, magnetization transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain and cervical cord damage in Leber's hereditary optic neuropathy. J Neurol Neurosurg Psychiatry 2001; 70: 444-9.
44. Inoue T, Hattori K, Ihara K, Ishii A, Nakamura K, Hirose S. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet 2013; 58: 548-52.
45. Isohanni P, Linnankivi T, Buzkova J, Lönnqvist T, Pihko H, Valanne L, et al. DARS2 mutations in mitochondrial leucoencepha-lopathy and multiple sclerosis. J Med Genet 2010; 47: 66-70.
46. Kappler J, Pötter W, Gieselmann V, Kiessling W, Friedl W, Propping P. Phenotypic consequences of low arylsulfatase A genotypes (ASAp/ASAp and ASA-/ASAp): does there exist an association with multiple sclerosis? Dev Neurosci 1991; 13: 228-31.
47. Karim MA, Suzuki K, Fukai K, Oh J, Nagle DL, Moore KJ, et al. Apparent genotype-phenotype correlation in childhood, adolescent, and adult Chédiak-Higashi syndrome. Am J Med Genet 2002; 108: 16-22.
48. Katz Sand IB, Lublin FD. Diagnosis and differential diagnosis of multiple sclerosis. [Review]. Continuum (Minneap Minn) 2013; 19: 922-43.
49. Kazibutowska Z, Bal A, Golba A, Lugowska A. Metachromatic leu-kodystrophy in adult patient initially diagnosed as multiple sclerosis. Neurol Neurochir Pol 2002; 36: 1209-19.
50. Keegan BM, Giannini C, Parisi JE, Lucchinetti CF, Boeve BF, Josephs KA. Sporadic adult-onset leukoencephalopathy with neu-roaxonal spheroids mimicking cerebral MS. Neurology 2008; 70: 1128-33.
51. Krupp L, Banwell B, Tenembaum S. International Pediatric MS Study Group Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007; 68 (Suppl 2): S7-12.
52. Küker W, Weir A, Quaghebeur G, Palace J. White matter changes in Leber's hereditary optic neuropathy: MRI findings. Eur J Neurol 2007; 14: 591-3.
53. Kumar AJ, Kohler W, Kruse B, Naidu S, Bergin A, Edwin D, et al. MR findings in adult-onset adrenoleukodystrophy. Am J Neuroradiol 1995; 16: 1227-37.
54. Labauge P, Dorboz I, Eymard-Pierre E, Dereeper O, Boespflug-Tanguy O. Clinically asymptomatic adult patient with extensive LBSL MRI pattern and DARS2 mutations. J Neurol 2011; 258: 335-7.
55. Lerman-Sagie T, Leshinsky-Silver E, Watemberg N, Luckman Y, Lev D. White matter involvement in mitochondrial diseases. Mol Genet Metab 2005; 84: 127-36.
56. Leuzzi V, Carducci C, Lenza M, Salvetti M, Ristori G, Di Giovanni S, et al. LHON mutations in Italian patients affected by multiple sclerosis. Acta Neurol Scand 1997; 96: 145-8.
57. Li R, Johnson AB, Salomons GS, van der Knaap MS, Rodriguez D, Boespflug-Tanguy O, et al. Propensity for paternal inheritance of de novo mutations in Alexander disease. Hum Genet 2006; 119: 137-44.
58. Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebro-spinal fluid: an update on methodology and clinical usefulness. [Review]. J Neuroimmunol 2006; 180: 17-28.
59. Lissens W, Arena A, Seneca S, Rafi M, Sorge G, Liebaers I, et al. A single mutation in the GALC gene is responsible for the majority of late onset Krabbe disease patients in the Catania (Sicily, Italy) region. Hum Mutat 2007; 28: 742.
60. Loes DJ, Fatemi A, Melhem ER, Gupte N, Bezman L, Moser HW, et al. Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology 2003; 61: 369-74.
61. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-11.
62. Lugowska A, Berger J, Tylki-Szymanska A, Löschl B, Molzer B, Zobel M, et al. Molecular and phenotypic characteristics of meta-chromatic leukodystrophy patients from Poland. Clin Genet 2005; 68: 48-54.
63. Mahad DJ, Ziabreva I, Campbell G, Lax N, White K, Hanson PS, et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009; 132: 1161-74.
64. Malojcic B, Brinar V, Poser C, Djakovic V. An adult case of Leigh disease. Clin Neurol Neurosurg 2004; 106: 237-40.
65. Maruyama S, Yamada T, Ishimoto Y, Hara H, Taniwaki T, Kira J. A case of MELAS showing CSF pleocytosis associated with stroke-like episodes. Rinsho Shinkeigaku 1998; 38: 641-4.
66. Matern D, Oglesbee D, Tortorelli S. Newborn screening for lysosomal storage disorders and other neuronopathic conditions. [Review]. Dev Disabil Res Rev 2013; 17: 247-53.
67. Miller DH, Leary SM. Primary progressive multiple sclerosis. [Review]. Lancet Neurol 2007; 6: 903-12.
68. Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008; 14: 1157-74.
69. Mo YH, Chen YF, Liu HM. Adrenomyeloneuropathy, a dynamic progressive disorder: brain magnetic resonance imaging in two cases. Neuroradiology 2004; 46: 296-300.
70. Moore DF, Ye F, Schiffmann R, Butman JA. Increased Signal Intensity in the Pulvinar on T1-Weighted Images: A Pathognomonic MR Imaging Sign of Fabry Disease. AJNR Am J Neuroradiol 2003; 24: 1096-101.
71. Naismith RT, Trinkaus K. Cross AH. Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review. Mult Scler 2006; 12: 775-81.
72. Natowicz MR, Bejjani B. Genetic disorders that masquerade as multiple sclerosis. [Review]. Am J Med Genet 1994; 49: 149-69.
73. Novarino G, Fenstermaker AG, Zaki MS, Hofree M, Silhavy JL, Heiberg AD, et al. Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders. Science 2014; 343: 506-11.
74. O'Riordan S, Nor AM, Hutchinson M. CADASIL imitating multiple sclerosis: the importance of MRI markers. Mult Scler 2002; 8: 430-2.
75. Palace J. Multiple sclerosis associated with Leber's hereditary optic neuropathy. J Neurol Sci 2009; 286: 24-7.
76. Padiath QS, Saigoh K, Schiffmann R, Asahara H, Yamada T, Koeppen A, et al. Lamin B1 duplications cause autosomal dominant leukodystrophy. Nat Genet 2006; 38: 1114-23.
77. Paradas C, Akman HO, Ionete C, Lau H, Riskind PN, Jones DE, et al. Branching enzyme deficiency: expanding the clinical spectrum. JAMA Neurol 2014; 71: 41-7.
78. Pareyson D, Fancellu R, Mariotti C, Romano S, Salmaggi A, carella F, et al. Adult-onset Alexander disease: a series of eleven unrelated cases with review of the literature. Brain 2008; 131: 2321-31.
79. Patil SA, Maegawa GH. Developing therapeutic approaches for meta-chromatic leukodystrophy. [Review]. Drug Des Devel Ther 2013; 7: 729-45.
80. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 2007; 6: 765-72.
81. Patterson MC, Mengel E, Wijburg FA, Muller A, Schwierin B, Drevon H, et al. Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J Rare Dis 2013; 8: 12.
82. Paulson HL, Garbern JY, Hoban TF, Krajewski KM, Lewis RA, Fischbeck KH, et al. Transient central nervous system white matter abnormality in X-linked Charcot-Marie-Tooth disease. Ann Neurol 2002; 52: 429-34.
83. Pinar-Sueiro S, Martínez-Fernández R, Lage-Medina S, Aldamiz-Echevarria L, Vecino E. Optic neuropathy in methylmalonic acide-mia: the role of neuroprotection. J Inherit Metab Dis 2010;; 33 ((Suppl 3): S199-203.
84. Pisani A, Visciano B, Roux GD, Sabbatini M, Porto C, Parenti G, et al. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. [Review]. Mol Genet Metab 2012; 107: 267-75.
85. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-6.
86. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
87. Prasad AN, Breen JC, Ampola MG, Rosman NP. Argininemia: a treatable genetic cause of progressive spastic diplegia simulating cerebral palsy: case reports and literature review. [Review]. J Child Neurol 1997; 12: 301-9.
88. Pretegiani E, Rufa A, Gallus GN, Cardaioli E, Malandrini A, Federico A. Spastic paraplegia in 'dominant optic atrophy plus' phenotype due to OPA1 mutation. Brain 2011; 134: e195.
89. Rademakers R, Baker M, Nicholson AM, Rutherford NJ, Finch N, Soto-Ortolaza A, et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet 2011; 44: 200-5.
90. Rafi MA, Rao HZ, Luzi P, Curtis MT, Wenger DA. Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease. Mol Ther 2012; 20: 2031-42.
91. Ramagopalan SV, Cukjati M, Cernilec M, DeLuca GC, Dyment DA, Degenhardt A, et al. Mutations in the hemochromatosis gene and the clinical outcome of multiple sclerosis. J Neuroimmunol 2008; 203: 104-7.
92. Raymond GV, Seidman R, Monteith TS, Kolodny E, Sathe S, Mahmood A, et al. Head trauma can initiate the onset of adreno-leukodystrophy. J Neurol Sci 2010; 290: 70-4.
93. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994; 117: 759-65.
94. Romagnolo A, Masera S, Mattioda A, Superti G, Santorelli FM, Mongini T, et al. Atypical hereditary spastic paraplegia mimicking multiple sclerosis associated with a novel SPG11 mutation. Eur J Neurol 2014; 21: e14-15.
95. Rudick RA, Schiffer RB, Schwetz KM, Herndon RM. Multiple sclerosis: the problem of incorrect diagnosis. [Review]. Arch Neurol 1986; 43: 578-83.
96. Rudick RA, Miller AE. Multiple sclerosis or multiple possibilities: the continuing problem of misdiagnosis. [Review]. Neurology 2012; 78: 1904-6.
97. Sato K, Kubo S, Fujii H, Okamoto M, Takahashi K, Takamatsu K, et al. Diffusion tensor imaging and magnetic resonance spectroscopy of transient cerebral white matter lesions in X-linked Charcot-Marie-Tooth disease. J Neurol Sci 2012; 316: 178-80.
98. Sedel F, Tourbah A, Fontaine B, Lubetski C, Baumann N, Saudubray JM, et al. Leukoencephalopathies associated with inborn errors of metabolism in adults. [Review]. J Inherit Metab Dis 2008; 31: 295-307.
99. Solomon AJ, Klein EP, Bourdette D. "Undiagnosing" multiple sclerosis: the challenge of misdiagnosis in MS. [Review]. Neurology 2012; 78: 1886-91.
100. Solomon AJ, Weinshenker BG. Misdiagnosis of multiple sclerosis: frequency, causes, effects, and prevention. [Review]. Curr Neurol Neurosci Rep 2013; 13: 403.
101. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006; 79: 31-40.
102. Stöckler S, Millner M, Molzer B, Ebner F, Körner E, Moser HW. Multiple sclerosis-like syndrome in a woman heterozygous for adre-noleukodystrophy. Eur Neurol 1993; 33: 390-2.
103. Stroobants S, Gerlach D, Matthes F, Hartmann D, Fogh J, Gieselmann V, et al. Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy. Hum Mol Genet 2011; 20: 2760-9.
104. Thauvin-Robinet C, Roze E, Couvreur G, Horellou MH, Sedel F, Grabli D, et al. The adolescent and adult form of cobalamin C disease: clinical and molecular spectrum. J Neurol Neurosurg Psychiatry 2008; 79: 725-8.
105. Tremlett H, Zhao Y, Devonshire V. Natural history of secondary progressive multiple sclerosis. [Review]. Mult Scler 2008; 14: 314-24.
106. Tschampa HJ, Greschus S, Vinahl M, Urbach H, Mueller MM, Gerding WM. MS-like presentation of Alexander disease with multi-focal lesions and oligoclonal bands. J Neurol 2011; 258: 935-7.
107. Van Geel BM, Bezman L, Loes DJ, Moser HW, Raymond GV. Evolution of phenotypes in adult male patients with X-linked adre-noleukodystrophy. Ann Neurol 2001; 49: 186-94.
108. Van Wassenaer-van Hall HN, van den Heuvel AG, Jansen GH, Hoogenraad TU, Mali WP. Cranial MR in Wilson disease: abnormal white matter in extrapyramidal and pyramidal tracts. Am J Neuroradiol 1995; 16: 2021-7.
109. Vyshkina T, Sylvester A, Sadiq S, Bonilla E, Canter JA, Perl A, et al. Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus. Clin Immunol 2008; 129: 31-5.
110. Wachowius U, Talley M, Silver N, Heinze HJ, Sailer M. Cognitive impairment in primary and secondary progressive multiple sclerosis. J Clin Exp Neuropsychol 2005; 27: 65-77.
111. Wang RY, Bodamer OA, Watson MS, Wilcox WR; ACMG Work Group on Diagnostic Confirmation of Lysosomal Storage DiseasesLysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med 2011; 13: 457-84.
112. Warshawsky I, Rudick RA, Staugaitis SM, Natowicz MR. Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutation. Ann Neurol 2005; 58: 470-3.
113. Weisfeld-Adams JD, Mehta L, Rucker JC, Dembitzer FR, Szporn A, Lublin FD, et al. Atypical Chédiak-Higashi syndrome with attenuated phenotype: three adult siblings homozygous for a novel LYST deletion and with neurodegenerative disease. Orphanet J Rare Dis 2013; 8: 46.
114. Williams R, Buchheit CL, Berman NE, LeVine SM. Pathogenic implications of iron accumulation in multiple sclerosis. [Review]. J Neurochem 2012; 120: 7-25.
115. Witte ME, Guerts JJ, de Vries HE, van der Valk P, van Horssen J. Mitochondrial dysfunction: a potential link between neuroinflamma-tion and neurodegeneration. [Review]. Mitochondrion 2010; 10: 411-18.
116. Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S. Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol 2013; 36: 78-83.
117. Yoshida T, Sasayama H, Mizuta I, Okamoto Y, Yoshida M, Riku Y, et al. Glial fibrillary acidic protein mutations in adult-onset Alexander disease: clinical features observed in 12 Japanese patients. Acta Neurol Scand 2011; 124: 104-8.
118. Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-Grumbach M, et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain 2010; 133: 771-86.
119. Zwetsloot CP, Padberg GW, van Seters AP, Maaswinkel-Mooy PD, Onkenhout W. Adult adrenoleukodystrophy: the clinical spectrum in a large Dutch family. J Neurol 1992; 239: 107-11.